IFIT1, IFIT2 and IFIT3 have been shown to be upregulated in cells infected with SARS-CoV-2, indicating activation of the interferon innate response, which could be regarded as potential drug targets for the treatment of COVID-19 (46–48). The gene discussed is IFIT3; the disease is COVID-19.